RETRANSMISSION: Chemaphor Announces Official Launch of Avivagen Animal Health Inc.
19 Noviembre 2010 - 7:00AM
Marketwired
Chemaphor Inc. (TSX VENTURE: CFR) and its subsidiary Avivagen
Animal Health Inc, today announced that Avivagen Animal Health has
officially launched its commercial operations this week. Avivagen
has begun marketing exclusively through the veterinary channel in
Canada its proprietary Oximunol™ Chewable Tablets for dogs and its
in-licensed VetStem RC regenerative cell treatment for dogs, horses
and cats.
Dave Hankinson, CEO of Chemaphor and Avivagen commented that "it
is gratifying that Chemaphor, through Avivagen, is now able to
enter the market with its first commercial products, which have
come to fruition after much effort expended on both the research
and development and the business development fronts. Our sales
representatives are finding considerable interest and excitement
across Canada among the veterinarians they visit, for both the
VetStem RC regenerative cell treatment and Oximunol™ Chewable
Tablets. Indeed, I am pleased to say that the first orders already
have been received by Avivagen, and that delivery is slated to
begin shortly."
At the same time, Chemaphor has launched a dedicated,
interactive website in support of Avivagen's products and services
(www.avivagen.com). Dave Hankinson remarked that "we believe it is
important to take full advantage of the social media capabilities
of online communities, to communicate with and build the
all-important, long-term relationships with pet parents and
veterinarians. At the same time this discussion creates awareness
of and buying interest in our novel and innovative products and
services. Accordingly, we have appointed a dedicated consumer and
marketing communications coordinator, Jennifer Febel, who will be
blogging on the website and facilitating discussion with website
visitors through services such as Facebook and Twitter, as well as
by regular email. Veterinarians who would like to discuss aspects
of our products and services, can contact Dr. Isabelle
Epshtein-Verzberger, our veterinary research scientist, whose
responsibilities include leading the canine clinical trials
program. Questions of a general nature can be directed to the
appropriate individual though the Avivagen customer service support
desk."
For further information please direct enquiries to any of the
appropriate resources listed below.
About Chemaphor
Chemaphor, a wellness company, is committed to developing and
delivering products to humans and animals to assist in optimizing
health and daily quality of life. Chemaphor is advancing product
candidates for the food animal market, companion animal market and
various, potential human applications. More information can be
found at www.chemaphor.com.
Forward Looking Statements
This news release includes certain forward-looking statements
that are based upon current expectations, which involve risks and
uncertainties associated with Chemaphor's business and the
environment in which the business operates. Any statements
contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the
expressions "anticipate", "believe", "plan", "estimate", "expect",
"intend", and similar expressions to the extent they relate to
Chemaphor or its management. The forward-looking statements are not
historical facts, but reflect Chemaphor's current expectations
regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from
current expectations. Chemaphor assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking
statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Chemaphor Inc. Graham Burton 613-990-0969
g.burton@chemaphor.com Avivagen Consumer and Marketing Enquiries
Jennifer Febel Consumer and Marketing Communications Associate
289-231-4417 j.febel@avivagen.com Avivagen Customer Service Number
1-855-210-2355 Avivagen Veterinary Enquiries Dr. Isabelle
Epshtein-Verzberger 902-940-7395 i.verzberger@avivagen.com Investor
Relations Evolution Group Inc. Sylvain Archambault President
1-866-703-4887 s.archambault@evolutiongrp.com
Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024